Abstract:Background: Afatinib is the only currently approved EGFR-tyrosine kinase inhibitors for advanced non-small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I. However, there are limited real-world data concerning the benefits and resistance mechanisms of afatinib in patients with these nonclassical mutations. To fill this gap, the present study was conducted. Methods: All NSCLC patients treated with afatinib were screened, and patients with EGFR G719X/L861Q/S768I were enrolled into the analysis. Either tumor tissue or blood specimens were detected by the commercial next-generation sequencing (NGS) panels or amplification-refractory mutation system (ARMS)-polymerase chain reaction (PCR) to figure out the mutation genotype. Results: A total of 106 advanced NSCLC patients with EGFR G719X/L861Q/S768I received afatinib treatment. The benefits of afatinib exhibited heterogeneity in different mutation genotypes. Notably, at baseline, NGS testing was performed in 59 patients, and TP53 was the most frequently coexisting mutation. Patients with TP53 mutations obtained fewer survival benefits than those with TP53 wild-type. A total of 68 patients ultimately experienced progression, and 27 patients received NGS testing to clarify the potential resistance mechanisms. EGFR-T790M, CDK4 amplification, FGFR1 amplification, PIK3CA, MET amplification, RET fusions, HER2, and BRAF mutations were identified in three (11.1%), three (11.1%), three (11.1%), three (11.1%), three (11.1%), one (3.7%), one (3.7%), and one (3.7%) of the cases, respectively. Five patients underwent ARMS-PCR testing for detecting EGFR-T790M mutation, and only one patient was T790M-positive. Conclusions: The present study elucidated the differential benefits of afatinib within different mutation genotypes and first revealed the spectrum of potential resistance mechanisms in patients with EGFR G719X/L861Q/S768I. The results of this study may provide practical clinical information that can guide optimal treatment in this setting.

A study of a multi‐source feedback system for international medical graduates holding defined licences

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

Critical Appraisal of the Role of Gefitinib in the Management of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib

A new background subtraction method for Western blot densitometry band quantification through image analysis software.

Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer.

LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer

Evaluation on the Use of Afatinib Alone or Combined with Other Drugs in Clinical Trials

Successful Treatment of a Patient with NSCLC Carrying Uncommon Compound L861Q/G719X Epidermal Growth Factor Receptor Mutations Using Afatinib

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

The Efficacy of Afatinib in Patients with HER2 Mutant Non-Small Cell Lung Cancer: a Meta-Analysis

[ Latest findings on hypereosinophilic syndrome].

Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With <i>EGFR</i> L718Q Mutation

EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib

Haptic Perception in Multimodal Virtual Environments - The Haptic Paradigm for Teaching and Learning

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry